Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1998-02-12
2000-09-19
Saunders, David
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
424 149, 4241531, 4241551, 4241781, 4241821, 4241831, 5303873, 53038873, 5303911, 5303913, 5303917, A61K 39395, C07K 1630
Patent
active
061207675
ABSTRACT:
A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses.
REFERENCES:
patent: 4468464 (1984-08-01), Cohen et al.
patent: 4486538 (1984-12-01), Bogoch
patent: 4650756 (1987-03-01), Old et al.
patent: 4708862 (1987-11-01), Baldwin
patent: 4724212 (1988-02-01), Epstein
patent: 4724213 (1988-02-01), Epstein
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5091178 (1992-02-01), Hellstrom et al.
patent: 5354847 (1994-10-01), Liu et al.
patent: 5500302 (1996-03-01), Phillips et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5545403 (1996-08-01), Page
patent: 5545404 (1996-08-01), Page
patent: 5545405 (1996-08-01), Page
patent: 5677180 (1997-10-01), Robinson et al.
patent: 5721108 (1998-02-01), Robinson et al.
IDEC Pharmaceuticals Corp. and Genentech, Inc., Product Sheet for Rituxan.RTM. (1998).
Barr, I.G. et al., "Retargeting of Cytolytic T Lymphocytes by Heteroaggregated (Bispecfic) Antibodies," Cancer Detection and Prevention 12:439-450 (1988).
Bodmer, M.W., "Recombinant Antibodies for Clinical Use," Abstracts of Oral Presentations, p. 526 (1986).
Boulianne, G.L. et al., "Production of Functional Chimaeric Mouse/Human Antibody," Nature 312:643-646 (Dec. 1984).
Brown, B.A. et al., "Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody," Cancer Research 47:3577-3583 (Jul. 1987).
Bruggemann, M. et al., "Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies," J. Exp. Med. 166:1351-1361 (Nov. 1987).
Cabilly, S. et al., "Generation of Antibody Activity from Immunoglobulin Polypeptide Chains Produced in Escherichia coli," Prod. Natl. Acad. Sci. USA 81:3273-3277 (Jun. 1984).
Clark, E.A. et al., "Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50," Proc. Natl. Acad. Sci. USA 83:4494-4498 (Jun. 1986).
Clark, E.A. et al., Abstract 0147--"Anti-Bp35 Antibody Induces Human B Cell Proliferation: Impliations for In Vivo Immunotherapy," Journal of Cellular Biochemistry (Supplement 9A), p. 63 (Jan./Feb. 1985).
European Search Report for EPO Application No. EP 115769.9 (Feb. 1988).
Gillies, S.D. et al., "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody," Hybridoma 10(3):347-356 (Jan. 1991).
International Search Report for PCT Application No. 88/03145 (Feb. 1988).
Jones, P.T. et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse," Nature 321:522-525 (May/Jun. 1986).
Liu, A.Y. et al., "Chimeric Mouse-Human IgG1 Antibody that can Mediate Lysis of Cancer Cells," Proc. Natl. Acad. Sci., USA 84:3439-3443 (May 1987).
Liu, A.Y. et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity," J. Immunol. 139:3521-3526 (Nov. 1987).
Marx, J.L., "Antibodies Made to Order," Science 229:455-456 (Aug. 1985).
Morrison, S.L. et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constrant Region Domains," Proc. Natl. Acad. Sci., USA 81:6851-6855 (Nov. 1984).
Morrison, S.L. et al., "Transfectomas Provide Novel Chimeric Antibodies," Science 229:1202-1207 (Sep. 1985).
Mujoo, K. et al., "A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD.sub.2," Cancer Immunology Immunotherapy 34:198-204 (1991).
Nadler, L.M. et al., "A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin," J. Clin. Invest. 67:134-140 (Jan. 1981).
Neuberger, M.S., "Making Novel Antibodies by Expressing Transfected Immunoglobulin Genes," TIBS, 10: 347-349 (Sep. 1985).
Neuberger, M.S., "A Hapten-Specific Chimaeric IgE Antibody with Human Physiological Effector Function," Nature 314:268-270 (Mar. 1985).
Neuberger, M.S., "Recombinant Antibodies Possessing Novel Effector Functions," Nature 312:604-608 (Dec. 1984).
Nishimura Y. et al., "Recombinant Human-House Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen," Canc. Res. 47:999-1005 (Feb. 1987).
Oi, V.T. et al., "Chimeric Antibodies," BioTechniques 4:214-221 (May/Jun. 1986).
Press, O. et al., Abstract 864--"Serotherapy of Malignant B Cell Lymphomas with Monoclonal Antibody 1F5 (ANTI-CD20)," Proceedings of the American Society of Clinical Oncology 5:221 (Mar. 1986).
Robinson, R.R. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biologial activities," Hum. Antibod. Hybridomas 2:84-93 (Apr. 1991).
Roit, I.M., "Essential Immunology," Blackwell Scientific Publications, Oxford, U.K., p. 165 (1984).
Sahagan, B.G. et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Asociated Antigen," J. Immunol. 137:1066-1074 (Aug. 1986).
Steplewski, Z. et al., "Biological Activity of Human-Mouse IgG1, IgG2, IgG3, and IgG4 Chimeric Monoclonal Antibodies with Antitumor Specificity," Proc. Natl. Acad. Sci., USA 85:4852-4856 (Jul. 1988).
Sun, L.K. et al., "Chimeric Antibody with Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A," Proc. Natl. Acad. Sci., USA 84:214-218 (Jan. 1987).
Sun, L.K. et al., "Chimeric Antibodies with 17-1A Derived Variable and Human Constant Regions," Hybridoma 5 Supp. 1:17-20 (Apr. 1986).
Takeda, S. et al., "Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences," Nature 314:452-454 (Apr. 1985).
Tan, L.K. et al., "A Human-Mouse Chimeric Immunoglobulin Gene with a Human Variable Region is Expressed in Mouse Myeloma Cells," J. Immunol. 135:3564-3567 (Nov. 1985).
Walker, C. et al., "Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell antibody: mechanism and subset-specific activation," Eur. J. Immunol. 17(6):873-880 (Jun., 1987).
Williams, G.T. et al., "Production of Antibody-Tagged Enzymes by Myeloma Cells: Application to DNA Polymerase I Klenow," Gene 43:319-324 (1986).
Wood, C.R. et al., "The Synthesis and In Vivo Assembly of Functional Antibodies in Yeast," Nature 314:446-449 (Apr. 1985).
Clark et al, Proc. Natl. Acad. Sci. USA, 82, 1776-1770, 1985.
Hellstrom et al, I N Baldwin et al, "Monoclonal Antibodies for Cancer Detection and Therapy", Academic Press, 1985, pp 34-36.
Stashenko et al, J. Immunol., 125, 1678-1685, 1980.
Nose et al, Proc. Natl. Acad. Sci. USA, 80, 6632-6636, 1983.
Ledbetter Jeffrey A.
Liu Alvin Y.
Robinson Randy R.
Bioventure Investments, kft
Pharmaceutical Royalties, L.L.C.
Saunders David
LandOfFree
Chimeric antibody with specificity to human B cell surface antig does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric antibody with specificity to human B cell surface antig, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric antibody with specificity to human B cell surface antig will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1069415